Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations.
Arvinas on Friday said the application covers vepdegestrant in patients with ER-positive/human epidermal growth factor receptor 2-negative ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy.
Clinical-stage biotechnology company Arvinas and drugmaker Pfizer in 2021 announced plans to collaborate on the development and commercialization of vepdegestrant, with the companies to share expenses and profits.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.